Compare Vanguard Mega Cap Growth ETF (MGK) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Organon & Co. Common Stock — how do they compare? Vanguard Mega Cap Growth ETF trades at $91.14 (market cap $33.70B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 9.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and Organon & Co. Common Stock for 0 Days on average.
| MGK | OGN | |
|---|---|---|
Market Cap | $33.70B | $3.62B |
Volume | 775,002 | 2,892,999 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $13.81 |
52-Week Low | $70.70 | $5.70 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $94.19, up 0.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, tracking large-cap U.S. growth stocks like Nvidia and Apple, lacks disclosed fundamental ratios but benefits from a low 0.05% expense ratio and recent positive media coverage highlighting its long-term growth potential and tech concentration.
The outlook for MGK is favorable for growth-oriented investors, driven by its focus on mega-cap tech leaders, though concentration risk and market volatility pose challenges. Analyst sentiment is broadly positive, with the ETF positioned to capitalize on sustained growth trends, but investors should weigh its reliance on top holdings against diversification needs.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
